EPY001, a Novel Monoclonal Antibody Against <i>Pseudomonas aeruginosa</i> Targeting OprF.

ABSTRACT: Pseudomonas aeruginosa (P. aeruginosa) is a high-priority opportunistic pathogen responsible for severe healthcare-associated infections exhibiting multidrug resistance, emphasizing the urgent need for alternative therapeutic strategies. Monoclonal antibodies (mAbs) targeting the highly conserved outer membrane protein OprF represent a promising approach to mitigate its infectivity. OprF, the major and highly conserved outer membrane protein of P. aeruginosa, plays key roles in the pathogenesis of this bacterium, including biofilm formation, host cell adhesion, immune sensing, and resistance to macrophage clearance, making it a crucial factor in virulence and a promising immunotherapeutic target. Here, we report the preclinical evaluation of EPY001, an anti-OprF mAb ge

SUBMITTER: Lacroix G 

PROVIDER: S-EPMC12609887 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature